Henry Schein stock (US42548G1040): Dental and medical distributor reports Q1 results and raises outlook for 2026

Henry Schein reports first?quarter 2026 results with modest revenue growth and an improved full?year outlook, highlighting continued demand in dental and medical markets.

Henry Schein has reported its first?quarter 2026 financial results, posting modest revenue growth and raising its full?year outlook as demand in dental and medical markets remains resilient. The company’s shares moved modestly in after?hours trading on Nasdaq, reflecting investor focus on margin trends and the updated guidance for 2026. The results and outlook were detailed in a press release and accompanying earnings call on May 7, 2026, according to Henry Schein investor relations as of May 7, 2026.

For the three months ended March 28, 2026, Henry Schein reported total revenue of about 3.0 billion USD, up roughly 3% year?over?year on a constant?currency basis, driven by growth in its dental and medical end?markets. Adjusted diluted earnings per share came in at 1.85 USD, above the prior?year quarter and slightly ahead of consensus estimates compiled by major financial data providers, according to Reuters as of May 7, 2026. The company cited improved operating leverage and disciplined cost management as key contributors to the earnings beat.

Management also raised its 2026 full?year guidance, now expecting adjusted diluted EPS in a range of 7.70–7.90 USD, up from the prior range of 7.50–7.70 USD, while maintaining a revenue growth outlook of about 3–4% on a constant?currency basis. The updated outlook reflects continued strength in dental practice activity, steady demand for medical supplies, and the ongoing integration of recent acquisitions, according to Henry Schein’s earnings release as of May 7, 2026. The company reiterated its focus on digital solutions, value?added services, and supply?chain efficiency to support long?term growth.

As of May 11, 2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Henry Schein, Inc.
• Sector/industry: Healthcare distribution and services
• Headquarters/country: Melville, New York, United States
• Core markets: Dental and medical practices in North America, Europe, and select international markets
• Key revenue drivers: Dental consumables and equipment, medical supplies, technology and software solutions, value?added services
• Home exchange/listing venue: Nasdaq Global Select Market (ticker: HSIC)
• Trading currency: USD

Henry Schein: core business model

Henry Schein operates as a leading global distributor of dental and medical products, equipment, and technology solutions, serving a broad base of dental and medical practitioners, group practices, and institutions. The company sources products from thousands of manufacturers and delivers them through a network of distribution centers, e?commerce platforms, and field sales teams. Its business model centers on providing a one?stop shop for consumables, equipment, and related services, which helps practices streamline procurement and reduce administrative burden.

The company’s dental segment includes consumables such as instruments, materials, and infection?control products, as well as equipment like dental chairs, imaging systems, and practice?management software. The medical segment focuses on supplies for physician offices, ambulatory surgery centers, and other healthcare settings, including personal protective equipment, diagnostic products, and specialty items. In addition to product distribution, Henry Schein offers value?added services such as practice consulting, financing solutions, and digital workflow tools that support practice efficiency and patient care.

For US investors, Henry Schein is notable as a healthcare?distribution play with exposure to both dental and medical end?markets, which tend to be relatively resilient to economic cycles. The company’s presence on Nasdaq and its listing in the S&P MidCap 400 index make it accessible to a wide range of retail and institutional investors seeking exposure to healthcare infrastructure and services.

Main revenue and product drivers for Henry Schein

Henry Schein’s revenue is primarily driven by recurring demand for dental consumables and equipment, which account for the largest share of its top line. Dental practices typically require a steady stream of consumables such as gloves, masks, burs, and restorative materials, creating a relatively predictable revenue base. Equipment sales, including dental chairs, imaging systems, and CAD/CAM units, contribute higher?margin but more cyclical revenue, often tied to practice expansions, renovations, or technology upgrades.

The medical segment has become an increasingly important growth driver, particularly as outpatient and ambulatory care settings expand. Demand for medical supplies used in physician offices, surgery centers, and long?term care facilities has been supported by aging demographics, chronic disease management, and the shift of procedures from hospitals to lower?cost settings. Henry Schein’s medical portfolio includes a broad range of products that support these trends, from basic supplies to more specialized items such as wound care and infection?control products.

Digital solutions and software platforms also play a growing role in the company’s revenue mix. Henry Schein offers practice?management software, imaging solutions, and integrated workflows that help dental and medical practices manage appointments, billing, and clinical documentation. These technology offerings not only generate recurring subscription and service revenue but also deepen customer relationships and create cross?selling opportunities for consumables and equipment.

Conclusion

Henry Schein’s first?quarter 2026 results and raised full?year outlook underscore the resilience of its dental and medical distribution business, supported by steady demand for consumables, equipment, and digital solutions. The modest revenue growth and improved earnings reflect effective cost management and operating leverage, while the updated guidance signals management’s confidence in continued market demand and execution.

For US investors, the stock offers exposure to a healthcare?distribution leader with a diversified customer base and a growing technology footprint, but it also carries risks related to pricing pressure, competition, and macroeconomic factors that could affect practice investment and elective procedures. As with any equity investment, investors should consider their risk tolerance, time horizon, and the broader healthcare and economic environment before making decisions.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.